Protein in the brain could be a key target in controlling Alzheimer's

January 25, 2012, Temple University

A protein recently discovered in the brain could play a key role in regulating the creation of amyloid beta, the major component of plaques implicated in the development of Alzheimer's disease, according to researchers at Temple University's School of Medicine.

A group led by Domenico Pratico, professor of and microbiology and immunology at Temple, discovered the presence of the , called 12/15-Lipoxygenase, in the brain three years ago.

"We found this protein to be very active in the brains of people who have Alzheimer's disease," said Pratico. "But three years ago, we didn't know the role it played in the development of the disease."

Following two years of study, the Temple researchers have found that the protein is at the top of a and controls a biochemical that begins the development of Alzheimer's. They have published their findings, "Transcriptional Regulation of ßsecretase-1 by 12/15 Lipoxygenase Results in Enhanced Amyloidogenesis and Cognitive Impairments," in the journal Annals of Neurology.

Pratico said that their research has shown that 12/15-Lipoxygenase controls Beta secretase (BACE-1), an enzyme that is key to the development of amyloid plaques in Alzheimer's patients.

"For reasons we don't yet know, in some people, 12/15-Lipoxygenase starts to work too much," he said. "By working too much, it sends the wrong message to the Beta secretase, which in turn starts to produce more amyloid Beta. This initially results in cognitive impairment, memory impairment and, later, an increase of amyloid ."

BACE-1 has long been a biological target for researchers seeking to create a drug against , said Pratico. But because little has been known about how it functions, they have been unsuccessful developing a molecule that could reach the brain and block it.

"We now know much better how Beta secretase works because we have found that the 12/15-Lipoxygenase protein is a controller of BACE functions," he said. "You don't need to target the Beta secretase directly because the 12/15-Lipoxygenase is really the system in the brain that tells BACE to work more or work less."

Pratico said that they have validated 12/15-Lipoxygenase as a target for a potential Alzheimer drug or therapy.

"By modulating BACE levels and activity through controlling the 12/15-Lipoxygenase, we can potentially improve the cognitive part of the phenotype of the disease, and prevent the accumulation of amyloid beta inside the neurons, which will eventually translate into less of those plaques," he said. "This is a totally new mechanism for controlling BACE."

Pratico said his group has looked at an experimental compound that blocks 12/15-Lipoxygenase function as a potential therapy to inhibit BACE function in the brain. In their lab, using animal models, they saw the drug's ability to restore some cognitive function, as well as improve learning and memory ability.

"There is an opportunity here to study this molecule and develop an even stronger molecule to target 12/15-Lipoxygenase function in the ," he said.

Explore further: Road block as a new strategy for the treatment of Alzheimer's

Related Stories

Road block as a new strategy for the treatment of Alzheimer's

August 22, 2011
Blocking a transport pathway through the brain cells offers new prospects to prevent the development of Alzheimer's. Wim Annaert and colleagues of VIB and K.U. Leuven discovered that two main agents involved in the inception ...

Recommended for you

Researchers target immune cells to slow progression of Amyotrophic Lateral Sclerosis

March 22, 2018
New research into Amyotrophic Lateral Sclerosis (ALS) - also known as motor neuron disease - shows that specific immune cells may help slow progression of the disease, an important step towards developing new therapies to ...

Focus on early stage of illness may be key to treating ALS, study suggests

March 22, 2018
A new kind of genetically engineered mouse and an innovation in how to monitor those mice during research have shed new light on the early development of an inherited form of amyotrophic lateral sclerosis (ALS).

Flow of spinal fluid disrupted in inherited developmental disorder

March 22, 2018
Scientists have pinpointed the mechanism behind hydrocephalus, an accumulation of cerebrospinal fluid around the brain, in an inherited developmental disorder called Noonan syndrome.

Obesity trigger identified within the human gut

March 22, 2018
The key chemical for happiness and sadness, serotonin, is also a force in our body's weight gain and calorie control, and scientists say more research could reduce obesity rates.

New wearable brain scanner allows patients to move freely for the first time

March 21, 2018
A new generation of brain scanner, that can be worn like a helmet allowing patients to move naturally whilst being scanned, has been developed by researchers at the Sir Peter Mansfield Imaging Centre, University of Nottingham ...

International team confirms new genetic mutation link to amyotrophic lateral sclerosis

March 21, 2018
Kinesin family member 5A (KIF5A), a gene previously linked to two rare neurodegenerative disorders, has been definitively connected to amyotrophic lateral sclerosis (ALS) by an international team from several of the world's ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.